Tsai Adam G, Juarez-Colunga Elizabeth, Felton Sue, Speer Rebecca B, Bessesen Daniel H, Atherly Adam J
Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, USA ; Anschutz Health and Wellness Center, University of Colorado School of Medicine, Aurora, USA ; Kaiser Permanente of Colorado, Departments of Internal Medicine and Metabolic-Surgical Weight Management, 2045 Franklin Street, 3rd Floor, Denver, USA.
Department of Biostatistics, Colorado School of Public Health, Aurora, USA.
BMC Obes. 2015 May 29;2:24. doi: 10.1186/s40608-015-0054-4. eCollection 2015.
Weight loss often leads to reductions in medication costs, particularly for weight-related conditions. We aimed to evaluate changes in medication costs from an 18 month study of weight loss among patients recruited from primary care.
Study participants (n = 79, average age = 56.3; 75.7 % female) with average BMI of 39.5 kg/m(2), plus one co-morbid condition of either diabetes/pre-diabetes, hypertension, abnormal cholesterol, or sleep apnea, were recruited from 2 internal medicine practices. All participants received intensive behavioral and dietary treatment during months 0-6, including subsidized access to portion-controlled foods for weight loss. From months 7-18, all participants were offered continued access to subsidized foods, and half of participants were randomly assigned to continue in-person visits ("Intensified Maintenance"), while the other half received materials by mail or e-mail ("Standard Maintenance"). Medication costs were evaluated at months 0, 6, and 18.
Participants assigned to Intensified Maintenance maintained nearly all their lost weight, whereas those assigned to Standard Maintenance regained weight. However, no significant differences in medication costs were observed within or between groups during the 18 months of the trial. A reduction of nearly $30 per month (12.9 %) was observed among all participants from month 0 to month 6 (active weight loss phase), but this difference did not reach statistical significance.
A behavioral intervention that led to clinically significant weight loss did not lead to statistically significant reductions in medication costs. Substantial variability in medication costs and lack of a systematic approach by the study team to reduce medications may explain the lack of effect.
The trial was registered at (NCT01220089) on September 23, 2010.
体重减轻通常会使药物成本降低,尤其是与体重相关的疾病。我们旨在评估一项针对从初级保健机构招募的患者进行的为期18个月的减肥研究中药物成本的变化。
从2个内科诊所招募了研究参与者(n = 79,平均年龄 = 56.3岁;75.7%为女性),平均体重指数为39.5kg/m²,伴有糖尿病/糖尿病前期、高血压、胆固醇异常或睡眠呼吸暂停中的一种共病情况。所有参与者在第0至6个月接受强化行为和饮食治疗,包括获得补贴以购买控制份量的减肥食品。从第7至18个月,所有参与者都能继续获得补贴食品,一半参与者被随机分配继续进行面对面就诊(“强化维持”),而另一半通过邮件或电子邮件接收材料(“标准维持”)。在第0、6和18个月评估药物成本。
分配到强化维持组的参与者几乎保持了所有减轻的体重,而分配到标准维持组的参与者体重反弹。然而,在试验的18个月内,组内或组间均未观察到药物成本的显著差异。从第0个月到第6个月(积极减肥阶段),所有参与者的药物成本每月减少近30美元(12.9%),但这一差异未达到统计学显著性。
一项导致临床上显著体重减轻的行为干预并未导致药物成本有统计学意义的降低。药物成本的巨大变异性以及研究团队缺乏减少药物使用的系统方法可能解释了这种无效性。
该试验于2010年9月23日在(NCT01220089)注册。